Strong scientific Support for Biohit’s GastroPanel in International Consensus Report
The latest international Maastricht/Florence Consensus Report on management of Helicobacter pylori infections recommends several indications of use for Biohit’s GastroPanel biomarkers. This report has been prepared by a wide panel of international experts. It gives very strong evidence of the benefits of GastroPanel test in diagnosing H. pylori infection, finding causes for dyspepsia and reflux symptoms, as well as evaluating risks for gastric and esophageal cancer, and early perception of them.
GastroPanel detects both H. pylori infection and atrophic gastritis (damage of stomach mucosa) that are the two most important risk factors of gastric cancer.
Biohit launched GastroPanel innovation that is based on four biomarkers (pepsinogen I, pepsinogen II, gastrin-17 and H. pylori IgG antibodies) at the beginning of this millennium. GastroPanel, together with the results reporting GastroSoft, is a unique blood-based test for primary diagnosis and screening purposes. This simple test provides fast, and cost-efficiently valuable clinical information in gastric and esophageal related problems.
The comprehensive Maastricht/Florence Reports are based on solid scientific evidence, and they have reached an important position among clinicians worldwide. The range of consensus statements included in the report cover all sub-topics encountered by clinicians in diagnosis and management of H. pylori infection and infection-related diseases and their risks.
The latest Maastricht/ Florence report supports growing demand for GastroPanel.
More comprehensive and specific summary of the latest Maastricht/Florence report and GastroPanel can be found at Biohit website (https://www.biohithealthcare.com/wp-content/uploads/2022/09/LT-Maastricht-VI-EN-3.pdf).
Additional information:
investor.relations@biohit.fi
www.biohithealthcare.com
Biohit in brief
Biohit Oyj is a globally operating Finnish biotechnology company. Biohit mission is “Innovating for Health” – we
produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in
Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit Series B share (BIOBV) is quoted on Nasdaq
Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com